Our Pipeline
Harnessing the therapeutic power of cannabinoids
We are developing a portfolio of prescription medicines that harness the therapeutic benefits of targeting the Endocannabinoid System (ECS) to treat people living with debilitating chronic neuropathic pain conditions that remain under-served by existing medicines.
Our approach is to make medicines that target an important biological system in the body, known as the Endocannabinoid System which plays an important role in maintaining the balance between our physical and mental health including regulating pain, mood, memory, sleep, appetite, and the immune response to cancer.
Where this balance becomes disrupted by disease, the aim is to restore it with rigorously tested and regulator-approved treatments that can be prescribed by physicians and reimbursed by insurers
We are working with three categories of compounds in our drug development pipeline:
New Chemical Entities (NCEs): These are fully synthetic molecules designed to interact with the endocannabinoid system, offering novel mechanisms of action distinct from plant-derived cannabinoids.
In-Licensed Compounds: Selected from leading pharmaceutical sources, these compounds are integrated into our portfolio to accelerate development timelines and enhance therapeutic potential.
Octavian Proprietary Compounds: A library of proprietary cannabinoid derivatives designed to optimise drug-like characteristics and expand treatment possibilities.
Our active programmes focus on neuropathic and inflammatory pain, including diabetic peripheral neuropathy (DPN), chemotherapy-induced peripheral neuropathy (CIPN), and inflammatory bowel syndrome (IBS); orphan disease indications, targeting an undisclosed rare condition; and oncology, focusing on an undisclosed new therapeutic target.
